Director at Schlich Ltd
George Schlich has a degree in natural sciences from Cambridge University, specialising in biology of cells, chemistry, pathology, physiology, mathematics, pharmacology and history and philosophy of science.
Founded in 2004, today Schlich has ten attorneys working on intellectual property relating to biotechnology, chemistry and mechanical subject matters. Schlich represents US company Intellia Therapeutics in IP proceedings related to CRISPR technology.
Mr Schlich started his career with a mix of small molecule chemistry from US pharmaceutical companies and, closer to home, stem cell inventions from the United Kingdom and missile guidance systems from the defence industry. He has considerable experience in the protection of inventions, including patents, designs, and trademarks, in areas from antibodies to bacteriophages; stem cells to breakfast cereals; small molecules to polymers; recombinant proteins to vaccines; cylinder locks to automobile accessories; and inhalation pharmaceuticals to cathode arc deposition of thin films. While he specialises in patents in the chemical and biochemical fields, Mr Schlich also advises on trademarks and designs. Schlich has successfully litigated design rights cases in the Intellectual Property Enterprise Court.
In recent years, Schlich has strategically advised start-up immuno-oncology clients as well as small to medium pharmaceutical and biotech companies and major corporate clients in Europe and the United States across the scope of their IP interests, supporting flotations on London’s Alternative Investment Market and NASDAQ.
Mr Schlich and his team also specialise in representing patent owners and opponents at inter partes hearings before the European Patent Office (EPO) and the UK Intellectual Property Office, and has extensive experience of EPO opposition and appeals.
Further afield, Schlich has worked on US discovery and interference proceedings, and also Section 1782 proceedings to support EPO opposition and appeal proceedings.
His published articles include “Broad Institute’s CRISPR/Cas9 Patent EP2771468 Revoked” and “Patent protection: why the first filing needs to be right and how to achieve this”.